September 11-13, 2020


Poster #65: Tolperisone 100 and 200 mg Three Times Daily (TID) for Acute Muscle Spasm of the Back: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase 3 Study



Randall Kaye, MD; Henry Riordan, PhD; Srinivas Nalamachu, MD; Joseph Pergolizzi, MD; Sanam Ara Vaughan

Key Highlights: Approximately 750 subjects are planned to be enrolled at about 60 clinical sites in the United States, with the first subject expected to be enrolled in Fall 2020. A second replicate Phase 3 study will be initiated at a later date.

Poster #75: Tolperisone for Acute Muscle Spasm: Dose-Ranging STAR Study



Srinivas Nalamachu, MD; Randall Kaye, MD; Joseph Pergolizzi, MD


Key Highlights: Tolperisone dose of 200 mg TID may be a promising treatment for the management of acute muscle spasm without the somnolence typically experienced with skeletal muscle relaxants.


Publication: Driving Study


An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine



Judy Caron PhD; Randall Kaye MD; Thomas Wessel MD, PhD; Amy Halseth PhD; Gary Kay PhD


What is new and conclusion: Subjects who received tolperisone (150 mg TID) experienced no impact on various measures of driving, self-reported sleepiness and cognition measures compared to placebo, in contrast to those who received the widely used muscle relaxant cyclobenzaprine (10 mg TID)

Publication: MEDPAGE TODAY


Novel Form of Muscle Relaxant Shows Benefit
— Tolperisone may help pain from acute back spasms without causing drowsiness



Judy George, Senior Staff Writer, MedPage Today September 5, 2020


Key Highlights:  Tolperisone, a centrally-acting muscle relaxant, may treat symptoms of acute muscle spasms without the sleepiness and cognitive effects associated with other skeletal muscle relaxants, data from the phase II STAR trial suggested.


4370 La Jolla Village Drive
Suite 860
San Diego, CA 92122
United States

© 2019 Neurana Pharmaceuticals. All Rights Reserved.